Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment

Research output: Contribution to journalArticle*Academicpeer-review


To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction > 50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-alpha) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis
Original languageEnglish
Pages (from-to)754-756
JournalExperimental Dermatology
Issue number8
Publication statusPublished - 2010

Cite this